TickerFacts.

A business in context

TEVA research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-09-07 · 8010 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 8-K · Current report

    Report date 2026-09-03 · 0001193125-26-381899 · Items 8.01,9.01

  2. 8-K · Current report

    Report date 2026-08-31 · 0001193125-26-381879 · Items 3.03,9.01

  3. 4 · Ownership change

    Report date 2026-08-21 · 0001193125-26-365116

  4. 4 · Ownership change

    Report date 2026-08-21 · 0001193125-26-365107

  5. 4 · Ownership change

    Report date 2026-08-17 · 0001193125-26-356853

  6. 4 · Ownership change

    Report date 2026-08-05 · 0001193125-26-341086

  7. 4 · Ownership change

    Report date 2026-08-03 · 0001193125-26-335026

  8. 4 · Ownership change

    Report date 2026-08-03 · 0001193125-26-335012

  9. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-323619

  10. 8-K · Current report

    Report date 2026-07-29 · 0001171843-26-004974 · Items 2.02,9.01

  11. 4 · Ownership change

    Report date 2026-06-18 · 0001193125-26-277490

  12. 4 · Ownership change

    Report date 2026-06-11 · 0001193125-26-271862

  13. 8-K · Current report

    Report date 2026-05-28 · 0001193125-26-245203 · Items 5.07

  14. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-191513

  15. 8-K · Current report

    Report date 2026-04-29 · 0001171843-26-002796 · Items 2.02,7.01,9.01

  16. DEF 14A · Proxy statement

    Report date 2026-05-28 · 0001193125-26-134756

  17. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-034532

  18. 8-K · Current report

    Report date 2026-01-28 · 0001171843-26-000462 · Items 2.02,9.01

  19. 8-K · Current report

    Report date 2026-01-11 · 0001171843-26-000174 · Items 2.02,9.01

  20. 8-K · Current report

    Report date 2025-12-10 · 0001193125-25-316063 · Items 1.01,2.03,9.01

  21. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-266895

  22. 8-K · Current report

    Report date 2025-11-05 · 0001171843-25-007000 · Items 2.02,9.01

  23. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001193125-25-169296

  24. 8-K · Current report

    Report date 2025-07-30 · 0001171843-25-004808 · Items 2.02,9.01

  25. 8-K · Current report

    Report date 2025-06-05 · 0001193125-25-135942 · Items 5.07

  26. 8-K · Current report

    Report date 2025-05-28 · 0001193125-25-129488 · Items 1.01,2.03,9.01

  27. 8-K · Current report

    Report date 2025-05-20 · 0001193125-25-125071 · Items 7.01,8.01,9.01

  28. 10-Q · Quarterly report

    Report date 2025-03-31 · 0001193125-25-114889

  29. 8-K · Current report

    Report date 2025-05-07 · 0001171843-25-002849 · Items 2.02,9.01

  30. DEF 14A · Proxy statement

    Report date 2025-06-05 · 0001193125-25-076829

  31. 10-K · Annual report

    Report date 2024-12-31 · 0001193125-25-020826

  32. 8-K · Current report

    Report date 2025-01-29 · 0001171843-25-000493 · Items 2.02,9.01

  33. 8-K · Current report

    Report date 2024-11-05 · 0001193125-24-256014 · Items 5.02

  34. SC 13G · Ownership disclosure

    0000315066-24-002849

  35. 10-Q · Quarterly report

    Report date 2024-09-30 · 0001193125-24-252039

  36. 8-K · Current report

    Report date 2024-11-06 · 0001171843-24-006034 · Items 2.02,9.01

  37. 10-Q · Quarterly report

    Report date 2024-06-30 · 0001193125-24-189924

  38. 8-K · Current report

    Report date 2024-07-31 · 0001171843-24-004270 · Items 2.02,9.01

  39. 8-K · Current report

    Report date 2024-06-23 · 0001193125-24-167489 · Items 1.01

  40. 8-K · Current report

    Report date 2024-06-06 · 0001193125-24-156043 · Items 5.07

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-09-07 · 2026 Q2: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 11 transaction rows11SGrant / award: 9 transaction rows9AExercise / conversion: 26 transaction rows26MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

46 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-06-18
2026-06-22
Shields MatthewS · Sale
Disposed
Ordinary Shares9989.032.19
2026-06-11
2026-06-16
Kalif Eliyahu SharonS · Sale
Disposed
Ordinary Shares106563.034.1
2026-06-05
2026-06-08
BARER SOL JM · Exercise / conversion
Acquired
Ordinary Shares21739.0—
2026-06-05
2026-06-08
BARER SOL JM · Exercise / conversion
Disposed
Restricted Share Units
Derivative security
21739.00.0
2026-06-05
2026-06-08
Lichtenstein ChenM · Exercise / conversion
Acquired
Ordinary Shares14492.0—
2026-06-05
2026-06-08
Lichtenstein ChenM · Exercise / conversion
Disposed
Restricted Share Units
Derivative security
14492.00.0
2026-06-05
2026-06-08
Crane Rosemary AM · Exercise / conversion
Acquired
Ordinary Shares14492.0—
2026-06-05
2026-06-08
Crane Rosemary AM · Exercise / conversion
Disposed
Restricted Share Units
Derivative security
14492.00.0
2026-06-05
2026-06-08
Elstein AmirM · Exercise / conversion
Acquired
Ordinary Shares14492.0—
2026-06-05
2026-06-08
Elstein AmirM · Exercise / conversion
Disposed
Restricted Share Units
Derivative security
14492.00.0
2026-06-05
2026-06-08
LIEBERMAN GERALD MM · Exercise / conversion
Acquired
Ordinary Shares14492.0—
2026-06-05
2026-06-08
LIEBERMAN GERALD MM · Exercise / conversion
Disposed
Restricted Share Units
Derivative security
14492.00.0
2026-06-05
2026-06-08
Nisen PerryM · Exercise / conversion
Acquired
Ordinary Shares14492.0—
2026-06-05
2026-06-08
Nisen PerryM · Exercise / conversion
Disposed
Restricted Share Units
Derivative security
14492.00.0
2026-06-05
2026-06-08
Satchi-Fainaro RonitM · Exercise / conversion
Acquired
Ordinary Shares14492.0—
2026-06-05
2026-06-08
Satchi-Fainaro RonitM · Exercise / conversion
Disposed
Restricted Share Units
Derivative security
14492.00.0
2026-06-05
2026-06-08
Zaks Tal ZviM · Exercise / conversion
Acquired
Ordinary Shares14492.0—
2026-06-05
2026-06-08
Zaks Tal ZviM · Exercise / conversion
Disposed
Restricted Share Units
Derivative security
14492.00.0
2026-06-05
2026-06-08
MIGNONE ROBERTOM · Exercise / conversion
Acquired
Ordinary Shares14492.0—
2026-06-05
2026-06-08
MIGNONE ROBERTOM · Exercise / conversion
Disposed
Restricted Share Units
Derivative security
14492.00.0
2026-06-05
2026-06-08
Francis Richard DS · Sale
Disposed
Ordinary Shares6153.034.35
2026-06-05
2026-06-08
Francis Richard DM · Exercise / conversion
Acquired
Ordinary Shares13043.0—
2026-06-05
2026-06-08
Francis Richard DM · Exercise / conversion
Disposed
Restricted Share Units
Derivative security
13043.00.0
2026-06-03
2026-06-04
Shields MatthewM · Exercise / conversion
Acquired
Ordinary Shares16195.0—
2026-06-03
2026-06-04
Shields MatthewS · Sale
Disposed
Ordinary Shares16195.032.87
2026-06-03
2026-06-04
Shields MatthewM · Exercise / conversion
Disposed
Restricted Share Units
Derivative security
16195.00.0
2026-05-28
2026-06-01
Zaks Tal ZviA · Grant / award
Acquired
Restricted Share Units
Derivative security
7242.00.0
2026-05-28
2026-06-01
Satchi-Fainaro RonitA · Grant / award
Acquired
Restricted Share Units
Derivative security
7242.00.0
2026-05-28
2026-06-01
Nisen PerryA · Grant / award
Acquired
Restricted Share Units
Derivative security
7242.00.0
2026-05-28
2026-06-01
LIEBERMAN GERALD MA · Grant / award
Acquired
Restricted Share Units
Derivative security
7242.00.0
2026-05-28
2026-06-01
Elstein AmirA · Grant / award
Acquired
Restricted Share Units
Derivative security
7242.00.0
2026-05-28
2026-06-01
Crane Rosemary AA · Grant / award
Acquired
Restricted Share Units
Derivative security
7242.00.0
2026-05-28
2026-06-01
Lichtenstein ChenA · Grant / award
Acquired
Restricted Share Units
Derivative security
7242.00.0
2026-05-28
2026-06-01
BARER SOL JA · Grant / award
Acquired
Restricted Share Units
Derivative security
10863.00.0
2026-05-28
2026-06-01
MIGNONE ROBERTOA · Grant / award
Acquired
Restricted Share Units
Derivative security
7242.00.0
2026-05-14
2026-05-18
Lippman EvanM · Exercise / conversion
Acquired
Ordinary Shares74008.0—
2026-05-14
2026-05-18
Lippman EvanS · Sale
Disposed
Ordinary Shares5746.035.58
2026-05-14
2026-05-18
Lippman EvanM · Exercise / conversion
Acquired
Ordinary Shares11841.0—
2026-05-14
2026-05-18
Lippman EvanS · Sale
Disposed
Ordinary Shares35912.035.58
2026-05-14
2026-05-18
Lippman EvanM · Exercise / conversion
Disposed
Restricted Share Units
Derivative security
11841.00.0
2026-05-14
2026-05-18
Lippman EvanM · Exercise / conversion
Disposed
Restricted Share Units
Derivative security
74008.00.0
2026-05-14
2026-05-18
Kalif Eliyahu SharonS · Sale
Disposed
Ordinary Shares153251.035.61
2026-05-06
2026-05-07
Weiss AmirS · Sale
Disposed
Ordinary Shares10679.036.0
2026-05-05
2026-05-07
Daniell RichardS · Sale
Disposed
Ordinary Shares30000.035.4
2026-05-01
2026-05-04
Sabag MarkS · Sale
Disposed
Ordinary Shares144180.034.99
2026-04-30
2026-05-04
Fox ChristineS · Sale
Disposed
Ordinary Shares21258.035.31

Identity & relationships

Wikidata structured data · retrieved 2026-09-07 · 1611 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0000818686TEVA PHARMACEUTICAL INDUSTRIES LTD
Teva Pharmaceuticals (Australia)Teva Pharmaceuticals (United States)Teva Pharmaceuticals (Ireland)Teva Pharmaceuticals (Hungary)Teva Pharmaceuticals (France)

Showing 5 of 5 imported Wikidata subsidiary claims. Additional aliases appear below.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-09-07 · 1177 checked identities; 0 unavailable records

Search names and former names

View Wikidata identity and references ↗

  • Teva Branded Pharmaceutical Products · alias · wikidata
  • Teva Branded Pharmaceutical Products R&D, Inc. · alias · wikidata
  • Teva Pharmaceuticals · alias · wikidata
  • Teva Pharmaceuticals (Australia) · subsidiary · wikidata
  • Teva Pharmaceuticals (United States) · subsidiary · wikidata
  • Teva Pharmaceuticals (Ireland) · subsidiary · wikidata
  • Teva Pharmaceuticals (Hungary) · subsidiary · wikidata
  • Teva Pharmaceuticals (France) · subsidiary · wikidata
  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED · former SEC name · 1996-02-02 to 2001-01-16
Explore headquarters map ↗

Revenue in constant purchasing power

USD revenue expressed in 2026-07 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$16.54B$17.61B
2023-12-31$15.85B$17.36B
2022-12-31$14.93B$17.03B
2021-12-31$15.88B$19.56B
2020-12-31$16.66B$21.49B
2019-12-31$16.89B$22.06B
2018-12-31$18.27B$24.30B
2017-12-31$21.85B$29.77B

Bureau of Labor Statistics · retrieved 2026-09-07 · 9 selected series; gaps remain missing

Explore the CPI history ↗